title: Oxidative stress and myocardial gene alterations associated with Doxorubicin-induced cardiotoxicity in rats persist for 2 months after treatment cessation.
abstract: The molecular mechanisms underlying doxorubicin (DOX)-induced cardiomyopathy include alterations in cardiomyocytes' oxidative stress status and in gene expression. Although such alterations have been reported during in vivo DOX treatment of animals, it remains to be clarified whether they persist after treatment cessation. To address this question, rats were injected with either saline (1 ml/kg/day i.p; control) or DOX (1 mg/kg/day i.p.) for 10 days, and 70 days later cardiac functional parameters were evaluated in vivo by left ventricular catheterization. Hearts were also harvested for histological analyses as well as measurements of oxidative stress parameters by various techniques and gene expression by quantitative polymerase chain reaction of markers of cardiac pathological remodeling, namely atrial natriuretic factor, myosin heavy chain β, vascular endothelial growth factor A (VEGF-A), and sarcoplasmic reticulum Ca(+2) ATPase. Compared with controls, DOX-treated rats displayed marked alterations in most parameters even 2 months after cessation of treatment. These included 1) lower left ventricular contractility (+dP/dt), 2) increased levels of plasma and myocardial oxidative stress markers, namely thiobarbituric acid reactive substances or dihydroethidium fluorescence, and 3) markedly altered transcript levels for all measured markers of cardiac remodeling, except VEGF-A. These changes correlated significantly with +dP/dt values assessed in the two groups of animals. In conclusion, this study demonstrated that as many as 2 months after cessation of DOX treatment cardiac alterations persisted, reflecting increased oxidative stress and pathological remodeling, the latter being linked to the development of contractile dysfunction.
authors.affiliation: Laboratoire de Physiopathologie and Pharmacologie Cardiovasculaires Expérimentales, EA 2979, IFR Santé-STIC, Facultés de Médecine and Pharmacie, 7 bd Jeanne d'Arc, 21000 Dijon, France.
authors.forename: Carole
authors.initials: C
authors.lastname: Richard
authors.forename: Steliana
authors.initials: S
authors.lastname: Ghibu
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Delemasure-Chalumeau
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Guilland
authors.forename: Christine
authors.initials: C
authors.lastname: Des Rosiers
authors.forename: Marianne
authors.initials: M
authors.lastname: Zeller
authors.forename: Yves
authors.initials: Y
authors.lastname: Cottin
authors.forename: Luc
authors.initials: L
authors.lastname: Rochette
authors.forename: Catherine
authors.initials: C
authors.lastname: Vergely
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology / Q000633:toxicity*; D001835:Body Weight / Q000187:drug effects; D054715:Cardiotoxins / Q000494:pharmacology / Q000633:toxicity*; D003094:Collagen / Q000032:analysis; D004317:Doxorubicin / Q000494:pharmacology / Q000633:toxicity*; D004353:Drug Evaluation, Preclinical; D005609:Free Radicals / Q000097:blood; D006331:Heart Diseases / Q000139:chemically induced / Q000235:genetics* / Q000473:pathology; D008297:Male; D009206:Myocardium / Q000473:pathology*; D018384:Oxidative Stress / Q000187:drug effects*; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D051381:Rats; D017208:Rats, Wistar; D013481:Superoxides / Q000032:analysis; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis; D013997:Time Factors; D020257:Ventricular Remodeling / Q000187:drug effects / Q000235:genetics*
chemical_list: D000903:Antibiotics, Antineoplastic; D054715:Cardiotoxins; D005609:Free Radicals; D012333:RNA, Messenger; D017392:Thiobarbituric Acid Reactive Substances; D013481:Superoxides; D004317:Doxorubicin; D003094:Collagen